Does the media prefer CGON or GENB?

In the previous week, CG Oncology had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 16 mentions for CG Oncology and 10 mentions for Generate Biomedicines. CG Oncology's average media sentiment score of 0.13 beat Generate Biomedicines' score of -0.01 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is GENB or COGT more profitable?

Generate Biomedicines' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Cogent Biosciences N/A -86.42% -48.97%

Does the media prefer GENB or COGT?

In the previous week, Cogent Biosciences had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for Cogent Biosciences and 10 mentions for Generate Biomedicines. Cogent Biosciences' average media sentiment score of 1.27 beat Generate Biomedicines' score of -0.01 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or GENB?

In the previous week, Mirum Pharmaceuticals had 18 more articles in the media than Generate Biomedicines. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 10 mentions for Generate Biomedicines. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat Generate Biomedicines' score of -0.01 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is SRRK or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -159.92% -90.71% Generate Biomedicines N/A N/A N/A

Does the media favor SRRK or GENB?

In the previous week, Scholar Rock had 10 more articles in the media than Generate Biomedicines. MarketBeat recorded 20 mentions for Scholar Rock and 10 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of -0.01 beat Scholar Rock's score of -0.01 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ORKA or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -28.80% -27.54% Generate Biomedicines N/A N/A N/A

Does the media prefer ORKA or GENB?

In the previous week, Oruka Therapeutics had 12 more articles in the media than Generate Biomedicines. MarketBeat recorded 22 mentions for Oruka Therapeutics and 10 mentions for Generate Biomedicines. Oruka Therapeutics' average media sentiment score of 0.49 beat Generate Biomedicines' score of -0.01 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Generate Biomedicines (GENB) Competitors

$15.68 +0.65 (+4.29%)

Closing price 03:59 PM Eastern

Extended Trading

$15.75 +0.07 (+0.48%)

As of 04:13 PM Eastern

Compare

GENB vs. CGON, COGT, MIRM, SRRK, and ORKA

Should you buy Generate Biomedicines stock or one of its competitors? Generate Biomedicines's main competitors and comparable companies include CG Oncology (CGON), Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Scholar Rock (SRRK), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Generate Biomedicines compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, CG Oncology had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 16 mentions for CG Oncology and 10 mentions for Generate Biomedicines. CG Oncology's average media sentiment score of 0.13 beat Generate Biomedicines' score of -0.01 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology currently has a consensus price target of $83.18, indicating a potential upside of 10.90%. Generate Biomedicines has a consensus price target of $25.40, indicating a potential upside of 62.04%. Given Generate Biomedicines' higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CG Oncology has higher earnings, but lower revenue than Generate Biomedicines. CG Oncology is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,645.65	-$160.99M	-$2.69	N/A
Generate Biomedicines	$31.89M	63.09	-$203.15M	-$1.59	N/A

Generate Biomedicines has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Generate Biomedicines' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-26.58%	-25.34%
Generate Biomedicines	N/A	N/A	N/A

Summary

CG Oncology beats Generate Biomedicines on 8 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Cogent Biosciences?

Generate Biomedicines (NASDAQ:GENB) and Cogent Biosciences (NASDAQ:COGT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Generate Biomedicines presently has a consensus price target of $25.40, indicating a potential upside of 62.04%. Cogent Biosciences has a consensus price target of $49.10, indicating a potential upside of 29.33%. Given Generate Biomedicines' higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for Cogent Biosciences and 10 mentions for Generate Biomedicines. Cogent Biosciences' average media sentiment score of 1.27 beat Generate Biomedicines' score of -0.01 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	63.09	-$203.15M	-$1.59	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Generate Biomedicines' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Cogent Biosciences	N/A	-86.42%	-48.97%

Summary

Generate Biomedicines beats Cogent Biosciences on 7 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Mirum Pharmaceuticals has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.52	-$23.36M	-$14.55	N/A
Generate Biomedicines	$31.89M	63.09	-$203.15M	-$1.59	N/A

Generate Biomedicines has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Generate Biomedicines' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Generate Biomedicines	N/A	N/A	N/A

Mirum Pharmaceuticals currently has a consensus price target of $137.33, suggesting a potential upside of 36.62%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 62.04%. Given Generate Biomedicines' higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Mirum Pharmaceuticals had 18 more articles in the media than Generate Biomedicines. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 10 mentions for Generate Biomedicines. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat Generate Biomedicines' score of -0.01 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Generate Biomedicines on 8 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Scholar Rock currently has a consensus target price of $57.71, suggesting a potential upside of 9.89%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 62.04%. Given Generate Biomedicines' higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Generate Biomedicines' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-159.92%	-90.71%
Generate Biomedicines	N/A	N/A	N/A

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Generate Biomedicines has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Generate Biomedicines	$31.89M	63.09	-$203.15M	-$1.59	N/A

In the previous week, Scholar Rock had 10 more articles in the media than Generate Biomedicines. MarketBeat recorded 20 mentions for Scholar Rock and 10 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of -0.01 beat Scholar Rock's score of -0.01 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Generate Biomedicines beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Generate Biomedicines' return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-28.80%	-27.54%
Generate Biomedicines	N/A	N/A	N/A

Oruka Therapeutics has higher earnings, but lower revenue than Generate Biomedicines. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Generate Biomedicines	$31.89M	63.09	-$203.15M	-$1.59	N/A

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oruka Therapeutics currently has a consensus price target of $134.30, suggesting a potential upside of 20.86%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 62.04%. Given Generate Biomedicines' higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Oruka Therapeutics had 12 more articles in the media than Generate Biomedicines. MarketBeat recorded 22 mentions for Oruka Therapeutics and 10 mentions for Generate Biomedicines. Oruka Therapeutics' average media sentiment score of 0.49 beat Generate Biomedicines' score of -0.01 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Oruka Therapeutics beats Generate Biomedicines on 7 of the 13 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.01B	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-9.86	10.55	269.56	25.30
Price / Sales	63.09	1,293.72	598.74	101.64
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	N/A	17.51	13.08	6.33
Net Income	-$203.15M	-$13.32M	$3.45B	$347.70M
7 Day Performance	9.23%	1.72%	1.11%	1.06%
1 Month Performance	10.31%	1.60%	1.79%	1.03%
1 Year Performance	N/A	56.45%	67.70%	20.73%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	1.6556 of 5 stars	$15.68 +4.3%	$25.40 +62.0%	N/A	$2.01B	$31.89M	N/A	312	Analyst Forecast Analyst Revision
CGON CG Oncology	2.4562 of 5 stars	$76.15 -0.5%	$83.18 +9.2%	+182.0%	$6.75B	$4.04M	N/A	61
COGT Cogent Biosciences	2.3958 of 5 stars	$38.88 -6.4%	$45.90 +18.1%	+211.4%	$6.65B	N/A	N/A	80	Positive News Earnings Report Analyst Forecast
MIRM Mirum Pharmaceuticals	3.5295 of 5 stars	$99.07 +0.4%	$137.33 +38.6%	+51.6%	$6.44B	$521.31M	N/A	140	Insider Trade Analyst Revision
SRRK Scholar Rock	1.74 of 5 stars	$52.01 +0.2%	$56.79 +9.2%	+65.9%	$6.34B	N/A	N/A	140	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. CGON, COGT, MIRM, SRRK, and ORKA

How does Generate Biomedicines compare to CG Oncology?

Summary

How does Generate Biomedicines compare to Cogent Biosciences?

Summary

How does Generate Biomedicines compare to Mirum Pharmaceuticals?

Summary

How does Generate Biomedicines compare to Scholar Rock?

Summary

How does Generate Biomedicines compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. CGON, COGT, MIRM, SRRK, and ORKA

How does Generate Biomedicines compare to CG Oncology?

Do insiders & institutionals believe in CGON or GENB?

Does the media prefer CGON or GENB?

Do analysts prefer CGON or GENB?

Which has better valuation and earnings, CGON or GENB?

Is CGON or GENB more profitable?

Summary

How does Generate Biomedicines compare to Cogent Biosciences?

Do analysts prefer GENB or COGT?

Does the media prefer GENB or COGT?

Which has higher earnings and valuation, GENB or COGT?

Is GENB or COGT more profitable?

Summary

How does Generate Biomedicines compare to Mirum Pharmaceuticals?

Which has stronger earnings & valuation, MIRM or GENB?

Is MIRM or GENB more profitable?

Do analysts recommend MIRM or GENB?

Does the media favor MIRM or GENB?

Summary

How does Generate Biomedicines compare to Scholar Rock?

Do analysts prefer SRRK or GENB?

Is SRRK or GENB more profitable?

Do insiders & institutionals hold more shares of SRRK or GENB?

Which has better valuation and earnings, SRRK or GENB?

Does the media favor SRRK or GENB?

Summary

How does Generate Biomedicines compare to Oruka Therapeutics?

Is ORKA or GENB more profitable?

Which has higher earnings & valuation, ORKA or GENB?

Do institutionals and insiders hold more shares of ORKA or GENB?

Do analysts rate ORKA or GENB?

Does the media prefer ORKA or GENB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools